These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 15926762)

  • 21. Effects of a prior-authorization policy for celecoxib on medical service and prescription drug use in a managed care Medicaid population.
    Hartung DM; Touchette DR; Ketchum KL; Haxby DG; Goldberg BW
    Clin Ther; 2004 Sep; 26(9):1518-32. PubMed ID: 15531015
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tegaserod for female patients suffering from IBS with mixed bowel habits or constipation: a randomized controlled trial.
    Chey WD; Paré P; Viegas A; Ligozio G; Shetzline MA
    Am J Gastroenterol; 2008 May; 103(5):1217-25. PubMed ID: 18477346
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Retrospective claims study of fluticasone propionate/salmeterol fixed-dose combination use as initial asthma controller therapy in children despite guideline recommendations.
    Friedman HS; Eid NS; Crespi S; Wilcox TK; Reardon G
    Clin Ther; 2009 May; 31(5):1056-63. PubMed ID: 19539106
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment failure rates and health care utilization and costs among patients with community-acquired pneumonia treated with levofloxacin or macrolides in an outpatient setting: a retrospective claims database analysis.
    Ye X; Sikirica V; Schein JR; Grant R; Zarotsky V; Doshi D; Benson CJ; Riedel AA
    Clin Ther; 2008 Feb; 30(2):358-71. PubMed ID: 18343274
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of tegaserod on esophageal pain threshold, regurgitation, and symptom relief in patients with functional heartburn and mechanical sensitivity.
    Rodriguez-Stanley S; Zubaidi S; Proskin HM; Kralstein JR; Shetzline MA; Miner PB
    Clin Gastroenterol Hepatol; 2006 Apr; 4(4):442-50. PubMed ID: 16616348
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effect of nonsteroidal anti-inflammatory drugs on the use of gastroprotective medication in people with arthritis.
    Lapane KL; Spooner JJ; Pettitt D
    Am J Manag Care; 2001 Apr; 7(4):402-8. PubMed ID: 11310194
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lack of association of tegaserod with adverse cardiovascular outcomes in a matched case-control study.
    Anderson JL; May HT; Bair TL; Muhlestein JB; Horne BD; Carlquist JF
    J Cardiovasc Pharmacol Ther; 2009 Sep; 14(3):170-5. PubMed ID: 19602672
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The economic effect of oral linezolid versus intravenous vancomycin in the outpatient setting: the payer perspective.
    McKinnon PS; Carter CT; Girase PG; Liu LZ; Carmeli Y
    Manag Care Interface; 2007 Jan; 20(1):23-34. PubMed ID: 17310650
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A naturalistic comparison of amoxicillin/clavulanate extended release versus immediate release in the treatment of acute bacterial sinusitis in adults: A retrospective data analysis.
    Jackson J; Fernandes AW; Nelson W
    Clin Ther; 2006 Sep; 28(9):1462-71. PubMed ID: 17062318
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Medication adherence and the associated health-economic impact among patients with type 2 diabetes mellitus converting to insulin pen therapy: an analysis of third-party managed care claims data.
    Lee WC; Balu S; Cobden D; Joshi AV; Pashos CL
    Clin Ther; 2006 Oct; 28(10):1712-25; discussion 1710-1. PubMed ID: 17157128
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Resource utilization with fluticasone propionate and salmeterol in a single inhaler compared with other controller therapies in children with asthma.
    Stempel DA; Riedel AA; Carranza Rosenzweig JR
    Curr Med Res Opin; 2006 Mar; 22(3):463-70. PubMed ID: 16574030
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Review article: the safety profile of tegaserod.
    Schoenfeld P
    Aliment Pharmacol Ther; 2004 Nov; 20 Suppl 7():25-30. PubMed ID: 15521852
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Costs of care for irritable bowel syndrome patients in a health maintenance organization.
    Levy RL; Von Korff M; Whitehead WE; Stang P; Saunders K; Jhingran P; Barghout V; Feld AD
    Am J Gastroenterol; 2001 Nov; 96(11):3122-9. PubMed ID: 11721759
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A clinical audit of the efficacy of tegaserod as a prokinetic agent in the intensive care unit.
    Stephens DP; Thomas JH; Collins SJ; Goldrick PB; Fowler S
    Crit Care Resusc; 2007 Jun; 9(2):148-50. PubMed ID: 17536982
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tegaserod and the risk of cardiovascular ischemic events: an observational cohort study.
    Loughlin J; Quinn S; Rivero E; Wong J; Huang J; Kralstein J; Earnest DL; Seeger JD
    J Cardiovasc Pharmacol Ther; 2010 Jun; 15(2):151-7. PubMed ID: 20200325
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Patterns of utilization for the Minnesota senior health options program.
    Kane RL; Homyak P; Bershadsky B; Flood S; Zhang H
    J Am Geriatr Soc; 2004 Dec; 52(12):2039-44. PubMed ID: 15571539
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Pharmacoeconomics and outcome research on Irritable Bowel Syndrome review of findings using Tegaserod].
    Ariza JG; Martínez JA
    Rev Gastroenterol Peru; 2006; 26(1):77-9. PubMed ID: 16622489
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Patterns of asthma-related health care resource use in children treated with montelukast or fluticasone.
    Allen-Ramey FC; Markson LE; Riedel AA; Sajjan S; Weiss KB
    Curr Med Res Opin; 2006 Aug; 22(8):1453-61. PubMed ID: 16870071
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Topiramate in migraine prophylaxis: long-term impact on resource utilization and cost.
    Silberstein SD; Feliu AL; Rupnow MF; Blount AC; Boccuzzi SJ
    Headache; 2007 Apr; 47(4):500-10. PubMed ID: 17445099
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An observational study of cholecystectomy in patients receiving tegaserod.
    Brinker A; Schech SD; Burgess M; Avigan M
    Drug Saf; 2007; 30(7):581-8. PubMed ID: 17604409
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.